COPSAC COPSAC COPSAC COPSAC
  • About COPSAC
    • About
    • Organization Diagram
    • Board of Directors
    • Research team
    • Location
    • Funding
    • Logo
    • Open positions
  • COPSAC cohorts
    • COPSAC2000 cohort
    • COPSAC2010 cohort
    • COPSACSEVERE cohort
    • COPSACACUTE cohort
    • Methods
    • Data overview
      • COPSAC2000 Clinic
      • COPSAC2000 Exposures
      • COPSAC2000 Omics
      • COPSAC2000 Biobank
      • COPSAC2010 Clinic
      • COPSAC2010 Exposures
      • COPSAC2010 Omics
      • COPSAC2010 Biobank
  • Dissemination
    • Theses
    • Literature for parents
  • Research Projects
    • RestoreGut
    • COPSYCH Research Alliance
    • HEDIMED Consortium
    • EDIAQI Consortium
    • EAGLE Consortium
    • EarlyVir
  • Strategy
  • ‌

Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged children.

    Home Publications Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged children.
    NextPrevious

    Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged children.

    By Dansk Børne Astma Center | Publications | Comments are Closed | 11 December, 2001 |

    Chest. 2001 Dec
    Bisgaard H, Price MJ, Maden C, Olsen NA.

    Abstract
    STUDY OBJECTIVES:
    To evaluate the cost-effectiveness of inhaled fluticasone propionate (FP) in children aged 12 to 47 months with asthma symptoms.

    DESIGN:
    A retrospective economic analysis conducted from the perspective of the Danish health-care system, based on clinical data from a 12-week study.

    SETTING:
    Thirty-three outpatient centers in nine countries.

    PATIENTS:
    Two hundred thirty-seven children aged 12 to 47 months with documented history of recurrent wheeze or asthma symptoms.

    INTERVENTIONS:
    Two dosages of FP, 100 microg/d and 200 microg/d, and placebo administered in two divided doses via a metered-dose inhaler and a Babyhaler (Glaxo Wellcome; Middlesex, UK) spacer device.

    MEASUREMENTS:
    Effectiveness in terms of asthma exacerbations, control of cough and wheeze symptoms, symptom-free days, overall direct costs of asthma management in Danish kroner at 1999 prices, and mean and incremental cost-effectiveness ratios.

    RESULTS:
    FP, 200 microg/d, was significantly more effective than placebo treatment in terms of the proportion of exacerbation-free patients (73.7% vs 59.8%; p = 0.025) and patients experiencing a > or = 25% improvement in cough symptoms (57.9% vs 39.0%; p = 0.018). The costs per exacerbation-free patient, per patient with a > or = 25% improvement in cough and wheeze symptoms from baseline, and per symptom-free day were lower in the FP groups than in the placebo group. The incremental cost-effectiveness ratios for these end points indicated that the additional benefits of FP, 200 microg/d, were achieved at a lower overall cost compared with placebo treatment.

    CONCLUSIONS:
    From the perspective of the Danish health-care system, FP, 100 microg bid, administered via the Babyhaler inhalation device was cost-effective
    relative to standard therapy with bronchodilators alone.

    Comment in
    Pharmacoeconomics in pediatric asthma. [Chest. 2001]
    Fluticasone vs placebo in toddlers with asthma: good science or questionable ethics? [Chest. 2002]

    PMID: 11742910

    No tags.
    NextPrevious

    CONTACT

    COPSAC
    Copenhagen Prospective Studies on Asthma in Childhood
    Copenhagen University Hospital, Herlev-Gentofte
    phone +45 3867 7360
    contact@copsac.com
    COPSAC • Copenhagen University Hospital, Herlev-Gentofte • Denmark © 2023
    • About COPSAC
      • About
      • Organization Diagram
      • Board of Directors
      • Research team
      • Location
      • Funding
      • Logo
      • Open positions
    • COPSAC cohorts
      • COPSAC2000 cohort
      • COPSAC2010 cohort
      • COPSACSEVERE cohort
      • COPSACACUTE cohort
      • Methods
      • Data overview
        • COPSAC2000 Clinic
        • COPSAC2000 Exposures
        • COPSAC2000 Omics
        • COPSAC2000 Biobank
        • COPSAC2010 Clinic
        • COPSAC2010 Exposures
        • COPSAC2010 Omics
        • COPSAC2010 Biobank
    • Dissemination
      • Theses
      • Literature for parents
    • Research Projects
      • RestoreGut
      • COPSYCH Research Alliance
      • HEDIMED Consortium
      • EDIAQI Consortium
      • EAGLE Consortium
      • EarlyVir
    • Strategy
    • ‌
    COPSAC